Boston Common Asset Management, LLC Biogen Inc. Transaction History

Boston Common Asset Management, LLC

$3.84 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 08, 2024	SELL	$190.52 - $236.72 $2.06 Million - $2.56 Million	-10,810 Reduced 23.88%	34,456 $7.99 Million
Q1 2024 Apr 11, 2024	SELL	$212.02 - $267.71 $2.85 Million - $3.6 Million	-13,445 Reduced 22.9%	45,266 $9.76 Million
Q4 2023 Jan 09, 2024	SELL	$222.59 - $267.94 $1.35 Million - $1.62 Million	-6,047 Reduced 9.34%	58,711 $15.2 Million
Q3 2023 Oct 11, 2023	BUY	$253.3 - $285.89 $6.3 Million - $7.11 Million	24,868 Added 62.34%	64,758 $16.6 Million
Q2 2023 Jul 24, 2023	SELL	$275.25 - $318.06 $31,929 - $36,894	-116 Reduced 0.29%	39,890 $11.4 Million
Q1 2023 May 17, 2023	BUY	$256.56 - $292.34 $711,697 - $810,951	2,774 Added 7.45%	40,006 $11.1 Million
Q4 2022 Jan 26, 2023	BUY	$252.44 - $306.72 $2,776 - $3,373	11 Added 0.03%	37,232 $10.3 Million
Q3 2022 Oct 20, 2022	SELL	$194.69 - $268.46 $6.95 Million - $9.58 Million	-35,692 Reduced 48.95%	37,221 $9.94 Million
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $352,950 - $419,723	-1,882 Reduced 2.52%	72,913 $14.9 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $6.39 Million - $8.05 Million	-32,976 Reduced 30.6%	74,795 $15.8 Million
Q4 2021 Jan 31, 2022	BUY	$223.92 - $287.77 $1.68 Million - $2.16 Million	7,511 Added 7.49%	107,771 $25.9 Million
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $7,640 - $9,964	-27 Reduced 0.03%	100,260 $28.4 Million
Q2 2021 Aug 19, 2021	BUY	$259.0 - $414.71 $15.7 Million - $25.1 Million	60,503 Added 152.08%	100,287 $34.7 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $1.23 Million - $1.44 Million	-5,070 Reduced 11.3%	39,784 $11.1 Million
Q4 2020 Feb 05, 2021	BUY	$236.26 - $355.63 $2.17 Million - $3.27 Million	9,191 Added 25.77%	44,854 $11 Million
Q3 2020 Nov 10, 2020	SELL	$264.77 - $305.71 $1.28 Million - $1.48 Million	-4,827 Reduced 11.92%	35,663 $10.1 Million
Q2 2020 Aug 10, 2020	BUY	$258.66 - $342.55 $707,435 - $936,874	2,735 Added 7.24%	40,490 $10.8 Million
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $69,901 - $88,670	260 Added 0.69%	37,755 $11.9 Million
Q4 2019 Jan 28, 2020	SELL	$220.06 - $304.07 $225,121 - $311,063	-1,023 Reduced 2.66%	37,495 $11.1 Million
Q3 2019 Nov 07, 2019	BUY	$217.44 - $243.88 $1.68 Million - $1.89 Million	7,745 Added 25.17%	38,518 $8.97 Million
Q2 2019 Jul 26, 2019	BUY	$219.29 - $241.72 $56,138 - $61,880	256 Added 0.84%	30,773 $7.2 Million
Q1 2019 May 03, 2019	BUY	$216.71 - $338.96 $1.29 Million - $2.01 Million	5,942 Added 24.18%	30,517 $7.21 Million
Q4 2018 Jan 25, 2019	BUY	$278.5 - $352.75 $571,482 - $723,843	2,052 Added 9.11%	24,575 $7.4 Million
Q3 2018 Nov 01, 2018	SELL	$293.51 - $383.83 $482,530 - $631,016	-1,644 Reduced 6.8%	22,523 $7.96 Million
Q2 2018 Aug 06, 2018	SELL	$257.52 - $306.91 $355,120 - $423,228	-1,379 Reduced 5.4%	24,167 $7.01 Million
Q1 2018 Apr 26, 2018	SELL	$260.13 - $367.91 $1.17 Million - $1.66 Million	-4,499 Reduced 14.97%	25,546 $7 Million
Q4 2017 Feb 07, 2018	BUY	$307.64 - $344.58 $427,311 - $478,621	1,389 Added 4.85%	30,045 $9.57 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $411,322 - $482,336	1,463 Added 5.38%	28,656 $8.97 Million
Q2 2017 Aug 14, 2017	BUY	N/A	27,193	27,193 $7.38 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

Vanguard Group Inc Valley Forge, PA

16.6M
Shares

$2.88 Billion
0.08% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.84 Billion
2.78% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.53 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.1M
Shares

$1.23 Billion
0.07% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

5.68M
Shares

$987 Million
0.83% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.

Account